Alkem Laboratories
Market cap ₹60,141 Cr
- P/E
- 27.88
- Day range
- ₹4,878.50 – ₹5,030.00
- 52-week range
- ₹4,811.00 – ₹5,933.50
- Volume
- 69,605
- Open
- ₹4,960.00
- Prev close
- ₹4,947.00
Latest results · Q1 FY27(consolidated)Revenue ₹3,740 Cr+10.9%Profit ₹521 Cr-22.0%Margin 13.9%YoY vs the same quarter last year
2 red flags to read up on
- medium
Promoter holding falling
49.70%, down 3.34 pts since 2025-06-30 · 30 Jun 2026
- medium
Material exchange filing
Announcement Under Regulation 30 (LODR)- Intimation Regarding Initiation Of Forensic Audit · 21 Oct 2026
From NSE and BSE filings. A flag is a reason to read the filing, not a rating.
ALKEM in NSE indices and F&O
F&O margin for one lot of ALKEM (125 shares)Research profile
Composite 64 / 100Factor percentiles
Derived metrics
- Earn. yield
- 3.6%
- Graham no.
- ₹2,243.20
- vs Graham
- -55.4%
- ROE ÷ P/B
- 4.3%
- 12-1 mom.
- -2.9%
- Return / vol
- -0.46
- Magic Formula
- #165
Appears in 8 scans
Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.
Peer comparison
All 67 in Pharma| Company | M-cap | P/E | P/B | ROE | ROCE | OPM | D/E | Sales YoY |
|---|---|---|---|---|---|---|---|---|
| Sun PharmaSUNPHARMA | ₹4.17 L Cr | 34.52 | 5.02 | 14.8% | 21.0% | 29.0% | 0.06 | +10.5% |
| Divi's LaboratoriesDIVISLAB | ₹2.40 L Cr | 82.12 | 14.18 | 16.2% | 22.0% | 41.0% | 0.00 | +27.8% |
| Torrent PharmaTORNTPHARM | ₹1.73 L Cr | 76.86 | 9.37 | 26.8% | 15.0% | 33.0% | 0.77 | +50.8% |
| Zydus LifesciencesZYDUSLIFE | ₹1.16 L Cr | 25.86 | 4.20 | 20.1% | 21.0% | 24.0% | 0.46 | +22.0% |
| Apollo HospitalsAPOLLOHOSP | ₹1.13 L Cr | 53.97 | 11.73 | 22.6% | 17.0% | 16.0% | 0.90 | +20.6% |
| Laurus LabsLAURUSLABS | ₹1.11 L Cr | 101.77 | 20.06 | 18.2% | 18.0% | 32.0% | 0.48 | +29.0% |
| CiplaCIPLA | ₹1.09 L Cr | 32.49 | 3.14 | 11.8% | 15.0% | 17.0% | 0.02 | +2.3% |
| Alkem LaboratoriesALKEM | ₹60,141 Cr | 27.88 | 4.28 | 18.2% | 21.0% | 20.0% | 0.15 | +10.9% |
| Sector median | ₹24,447 Cr | 41.53 | 5.60 | 15.1% | 17.0% | 25.0% | 0.16 | +20.7% |
Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.
Latest news
Updated 9d agoHeadlines about Alkem Laboratories from the last two weeks in the financial press. Stories belong to their publishers; Parasram India does not endorse them.
Key metrics
- P/E (TTM)
- 26.0
- EPS (TTM)
- ₹180.45
- Price / Book
- 4.35
- ROE (FY26)
- 18.2%
- ROCE (latest year)
- 21%
- Dividend yield
- 1.07%
Moving averages (NSE)
- 20-day
- ₹5,178.9
- Price below
- 50-day
- ₹5,257.56
- Price below
- 200-day
- ₹5,456.71
- Price below
Charts & trends
From company filings. Amounts in ₹ crore.
Revenue, profit & margin - quarterly
₹ crore; a loss shows red. Operating margin below, same periods.
- Revenue
- Net profit
Operating margin
Who owns the company
% of equity by quarter, latest Sept 2026
- Promoter
- DII
- Public
- FII
Cash flows
Where cash came from and went, by fiscal year (₹ crore)
- Operating
- Investing
- Financing
- Free cash flow
Return on equity
Net profit over shareholders' equity, by fiscal year
Equity vs debt
Shareholders' equity against borrowings (₹ crore); the ratio below, same years.
- Equity
- Debt
Debt to equity
Dividends per share
₹ by fiscal year of the ex-date; the latest year runs to date.
Financial statements
| Line item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,440 | 3,324 | 2,936 | 3,032 | 3,415 | 3,374 | 3,144 | 3,371 | 4,001 | 3,737 | 3,603 | 3,740 |
| Expenses | 2,693 | 2,616 | 2,534 | 2,423 | 2,662 | 2,615 | 2,752 | 2,632 | 3,080 | 2,909 | 3,086 | 2,974 |
| Operating Profit | 747 | 708 | 402 | 609 | 753 | 759 | 391 | 739 | 921 | 828 | 517 | 766 |
| OPM % | 22% | 21% | 14% | 20% | 22% | 23% | 12% | 22% | 23% | 22% | 14% | 20% |
| Other Income | 6 | 42 | 76 | 120 | 134 | 93 | 146 | 149 | 104 | 90 | 65 | 153 |
| Interest | 30 | 25 | 27 | 29 | 28 | 36 | 28 | 30 | 35 | 42 | 54 | 47 |
| Depreciation | 74 | 70 | 83 | 80 | 79 | 85 | 112 | 88 | 94 | 95 | 106 | 100 |
| Profit before tax | 648 | 655 | 367 | 619 | 780 | 731 | 396 | 771 | 896 | 781 | 423 | 772 |
| Tax % | 5% | 8% | 17% | 11% | 10% | 12% | 18% | 13% | 13% | 16% | 40% | 32% |
| Net Profit | 615 | 604 | 304 | 550 | 702 | 641 | 322 | 668 | 779 | 653 | 251 | 521 |
| EPS in Rs | ₹51.90 | ₹49.76 | ₹24.55 | ₹45.60 | ₹57.60 | ₹52.34 | ₹25.58 | ₹55.56 | ₹63.99 | ₹53.19 | ₹19.78 | ₹43.49 |
From company filings, updated 26 Oct 2026. Consolidated figures where the company reports them. Information only, not investment advice.
Working-capital cycle
+8 days since Mar 2021
-2 days since Mar 2021
+49 days since Mar 2021
-44 days since Mar 2021
+75 days since Mar 2021
Strengths, risks & growth
Alkem Laboratories is engaged in pharmaceutical business with global operations. The Company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products.(Source : 202003-01 Annual Report Page No:107)
Strengths
- Company has been maintaining a healthy dividend payout of 26.3%
Risks
- The company has delivered a poor sales growth of 10.7% over past five years.
- Promoter holding has decreased over last 3 years: -7.04%
Compounded Sales Growth
- 10 Years
- +12%
- 5 Years
- +11%
- 3 Years
- +8%
- TTM
- +13%
Compounded Profit Growth
- 10 Years
- +12%
- 5 Years
- +9%
- 3 Years
- +32%
- TTM
- 0%
Stock Price CAGR
- 10 Years
- +12%
- 5 Years
- +6%
- 3 Years
- +10%
- 1 Year
- -11%
Return on Equity
- 10 Years
- +18%
- 5 Years
- +18%
- 3 Years
- +19%
- Last Year
- +19%
Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.
Shareholding pattern
| Holder | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 | Change |
|---|---|---|---|---|---|
| Promoter | 51.20% | 51.20% | 49.70% | 49.70% | 0.00 pp |
| FII | 9.97% | 10.15% | 10.42% | 10.32% | -0.10 pp |
| DII | 21.54% | 21.39% | 22.64% | 22.83% | +0.19 pp |
| Public | 17.30% | 17.25% | 17.25% | 17.14% | -0.11 pp |
Filed with NSE for Jun 2026: promoters 49.70%, public 50.30% · XBRL filing
Analysts & fund holdings
Who holds the shares, quarter by quarter
Mutual funds 17.79% (+1.08 pp)- Promoters49.7%
- Foreign institutions10.3%
- Mutual funds17.8%
- Insurance3.1%
- Other domestic institutions1.9%
- Retail1.1%
- Others16.0%
| Fund | % of company | % of fund | 3-month change |
|---|---|---|---|
| HDFC Mid Cap Fund | 2.90% | 1.72% | -0.03 pp |
| ICICI Pru Multi Asset Allocation Fund | 1.38% | 0.95% | -0.06 pp |
| SBI Large & Midcap Fund | 1.32% | 1.88% | -0.13 pp |
| Nippon India Growth Mid Cap Fund | 1.05% | 1.27% | -0.05 pp |
| Axis Midcap Fund | 0.76% | 1.37% | +0.52 pp |
Scorecard
- Performance
- Low
- Valuation
- High
- Growth
- Avg
- Profitability
- High
- Entry point
- Good
- Red flags
- Low
Analyst coverage, holdings and scorecard from market data; not a recommendation by Parasram India.
Risk & trend
From 275 daily sessions to 23 Oct 2026.
Risk
- Volatility (1Y)
- 21.5%
- Downside volatility
- 22.5%
- Worst 5% of days
- 1.9%
- Average of that tail
- 2.9%
- Max drawdown (1Y)
- 16.0%
- Below its peak
- 16.0%
Against the market
- Beta vs Nifty 50
- 0.67
- Correlation
- 0.42
- Relative strength (3M)
- -6.4%
- ATR (14)
- 2.6%
Return
- Return 1M
- -7.2%
- Return 3M
- -11.7%
- Return 6M
- -12.1%
- Return 1Y
- -9.9%
- vs 200-day average
- -9.3%
Momentum
- RSI (14)
- 33.9
- MACD histogram
- -26.19
- Stochastic %K
- 22.8
- ADX (14)
- 21.2
- +DI / −DI
- 9.8 / 26.0
- Money flow index
- 29.6
Participation
- Delivery (20d avg)
- 56.6%
- vs its 60-day baseline
- -0.1 pts
- Volume vs 20-day
- -1.1σ
- Close vs day's VWAP
- +0.4%
- 52-week position
- 0 / 100
These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.
Financial quality
From consolidated statements to 30 Jun 2026.
No F-Score: it needs two reporting periods a year apart that carry both an income statement and a balance sheet, and this company's filings do not yet line up that way. The ratios below need only the one period and are unaffected.
- Revenue CAGR
- 10.9%
- Profit CAGR
- -21.7%
Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.
Insider trades
| Person | Type | Shares | Value | Disclosed |
|---|---|---|---|---|
Deepak Kumar Singh Employees/Designated Employees · Market Sale | Sell | 25,000 | ₹9.0 Cr | 29 Mar 2022 |
Mritunjay Kumar Singh Director · Market Purchase | Buy | 3,357 | ₹1.1 Cr | 8 Mar 2022 |
Mritunjay Kumar Singh Director · Market Purchase | Buy | 1,643 | ₹51.9 L | 8 Mar 2022 |
Dhananjay and Madhurima Singh Trust Promoters · Market Purchase | Buy | 1,050 | ₹34.4 L | 25 Feb 2022 |
Dhananjay and Madhurima Singh Trust Promoters · Market Purchase | Buy | 2,000 | ₹65.9 L | 23 Feb 2022 |
Deepak Kumar Singh Employees/Designated Employees · Market Sale | Sell | 2,000 | ₹69.8 L | 30 Dec 2021 |
Deepak Kumar Singh Employees/Designated Employees · Market Sale | Sell | 2,000 | ₹68.7 L | 27 Dec 2021 |
Deepak Kumar Singh Employees/Designated Employees · Market Sale | Sell | 5,000 | ₹1.7 Cr | 23 Dec 2021 |
Jayanti Sinha Promoter Group · Gift | Sell | 20,00,000 | ₹0 | 2 Dec 2021 |
Deepak Kumar Singh Employees/Designated Employees · Market Sale | Sell | 5,000 | ₹1.8 Cr | 18 Nov 2021 |
Balmiki Prasad Singh Director · Off Market | Buy | 50,266 | ₹0 | 5 Oct 2021 |
Satish Kumar Singh Promoters · Off Market | Buy | 50,267 | ₹0 | 5 Oct 2021 |
Disclosures filed with NSE under SEBI (Prohibition of Insider Trading) Regulations. Pledges and releases are not trades and are not counted above.
Corporate actions
- dividend₹10.00
Dividend - Rs 10 Per Share
7 Aug 2026ex-date - dividend₹43.00
Interim Dividend - Rs 43 Per Share
20 Feb 2026ex-date - dividend₹8.00
Dividend - Rs 8 Per Share
8 Aug 2025ex-date - dividend₹37.00
Interim Dividend - Rs 37 Per Share
14 Feb 2025ex-date - dividend₹5.00
Dividend - Rs 5 Per Share
9 Aug 2024ex-date - dividend₹35.00
Interim Dividend - Rs 35 Per Share
16 Feb 2024ex-date - dividend₹10.00
Dividend - Rs 10 Per Share
10 Aug 2023ex-date - dividend₹15.00
Interim Dividend - Rs 15 Per Share & Special Dividend Rs 25 Per Share
17 Feb 2023ex-date - dividend₹4.00
Dividend - Rs 4 Per Share
8 Aug 2022ex-date - dividend₹30.00
Interim Dividend - Rs 30 Per Sh
10 Feb 2022ex-date - dividend₹5.00
Dividend - Rs 5 Per Share
9 Aug 2021ex-date - dividend₹25.00
Interim Dividend - Rs 25 Per Share
11 Feb 2021ex-date - dividend₹3.00
Annual General Meeting/Dividend - Rs 3 Per Share
10 Aug 2020ex-date - dividend₹22.00
Interim Dividend - Rs 22 Per Share
13 Feb 2020ex-date - dividend₹8.00
Annual General Meeting/Dividend - Rs 8 Per Share
19 Aug 2019ex-date - dividend₹8.00
Interim Dividend - Rs 8 Per Share
15 Feb 2019ex-date - dividend₹7.00
Annual General Meeting/Dividend- Rs 7 Per Share
23 Aug 2018ex-date - dividend₹6.00
Interim Dividend - Rs 6 Per Share (Purpose Revised)
16 Feb 2018ex-date - dividend₹9.00
Annual General Meeting/ Dividend -Rs 9/- Per Share
31 Aug 2017ex-date - dividend₹6.00
Interim Dividend Rs 6/- Per Share
23 Nov 2016ex-date
Company announcements
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Para A of Part A of Schedule III thereto, we wish to inform you that ....
Please find attached herewith intimation for appointment of Mr. Laxmikant Tiwari and Mr. Nilesh Vartak as Senior Management Personnels of the Company.
Please find attached herewith intimation for change in Key Managerial Personnel - Resignation of Chief Financial Officer
Please find attached herewith intimation of Schedule of Analyst / Institutional Investor Meeting.
Please find attached herewith intimation for closure of trading window.
Please find attached herewith intimation for issue of corporate guarantee by the Company.
Alkem Laboratories Limited launches NeuCeno (cenobamate) for the treatment of partial - onset seizures in adult patients.
Please find attached herewith intimation for appointment of Dr. Shubhadeep Sinha as Senior Management Personnel of the Company.
Alkem Laboratories Limited launches Renocia ExoTM, India's first patented Ginsenoside Exosome - based hair growth serum
Please find attached herewith Scrutinizer Report for 52nd Annual General Meeting of the Company.
Please find attached herewith Outcome of the 52nd Annual General Meeting of the Company and disclosure of voting results thereat.
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for HDFC Mutual Fund
Please find attached herewith Q1 FY27- Earnings Call Transcript.
Please find attached herewith Q1 FY27- Earnings Call Transcript.
Please find attached herewith Proceedings of the meeting of the equity shareholders of the Company and Scrutinizer's Report on e-voting.
Filed with BSE (scrip 539523); the last 45 days. Documents open at bseindia.com.
SEBI filings & orders
From SEBI's website. An order may concern the company, its officers or trading in its shares, and may be under appeal - read the order itself. Personal identifiers are withheld.
Regulatory orders
- Settlement order
Settlement Order in respect of IIFL Securities Limited in the matter of Alkem Laboratories Ltd.
25 Feb 2022Read on SEBI - Order
Order in the matter of Alkem Laboratories Limited.
10 Mar 2017Read on SEBI
Documents
Annual reports
Earnings calls
- Aug 2026Transcript
- Aug 2026TranscriptSlidesRecording
- Jun 2026TranscriptSlides
- Feb 2026Slides
- Feb 2026TranscriptSlides
- Feb 2026Slides
Credit ratings
- Rating update · 8 Jul from crisil
- Rating update · 24 Feb from crisil
- Rating update · 6 Feb from fitch
- Rating update · 5 Jan from care
- Rating update · 15 Sep 2025 from crisil
- Rating update · 7 Feb 2025 from fitch
Documents open at BSE or the rating agency that issued them.
Sourced from the company's NSE XBRL filing dated 14 Aug 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.
Alkem Laboratories: common questions
Answered from the figures on this page.
